
REVIEW

The Immune Tolerance Network and Rheumatic Disease

Immune Tolerance Comes to the Clinic

Betty Diamond,¹ Jeffrey Bluestone,² and David Wofsy²

Autoimmune diseases pose some of the most baffling scientific questions and daunting clinical challenges in internal medicine. With rare exception, we do not know what causes these diseases, and we have neither safe nor sufficiently effective therapies. Thus, in rheumatoid arthritis (RA), we define success as a 20% improvement in 50% of patients. In systemic lupus erythematosus (SLE), we define success in treating nephritis as prevention of end-stage renal disease, often at the cost of producing iatrogenic Cushing's syndrome, infertility, or worse. Although these definitions of success leave much to be desired, they do represent substantial progress in recent decades. Crippling disability is now less likely in patients with RA, and death is less likely in patients with SLE. This progress is a consequence of many factors, including advances in general medical care and orthopedic surgery, new antiinflammatory drugs, more judicious and effective use of immunosuppressive agents, and better antibiotics. Yet, all these advances relate to improved immunosuppression and require ongoing medication to suppress autoreactivity.

Thus, the ultimate goal of research in these diseases remains elusive. In clinical terms, that goal is to prevent or selectively ablate pathologic immune responses without damaging protective immune responses. In scientific terms, that translates into maintaining or restoring immune tolerance. The goal of achieving tolerance will be met when patients remain well without requiring ongoing intervention.

Dramatic recent advances in our understanding

of the basic mechanisms of the immune system have led many to believe that the ability to achieve immune tolerance in patients with autoimmune disease may be close at hand. In recognition of this exciting prospect, the National Institutes of Health established the Immune Tolerance Network (ITN) on September 30, 1999 (see <http://www.immunetolerance.org>). The ITN is funded as a joint effort by the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Juvenile Diabetes Foundation International. The Network is mandated to initiate and oversee clinical trials of new therapies designed to produce long-lasting immune tolerance in situations where the immune response is harmful, such as in autoimmune diseases, allergic responses, and transplant rejection. To accomplish this goal, the ITN has established a steering committee of more than 70 world leaders in immune tolerance, both basic scientists and clinicians, whose charge is to solicit, review, and coordinate clinical trials of new, biologically based strategies to achieve immune tolerance.

An additional innovative feature of the ITN is that all trials will be coupled to mechanistic studies so that we can better understand how clinical protocols designed to induce tolerance actually alter the function (both the protective and the pathogenic responses) of the immune system. The mechanistic studies will also advance other important goals, including development of markers for a tolerant state and identification of genes that are associated with a therapeutic response or lack of response to a particular immunologic intervention.

Immune activation

The development of rational strategies to promote immune tolerance requires a thorough under-

¹Betty Diamond, MD: Albert Einstein College of Medicine, Bronx, New York; ²Jeffrey Bluestone, MD, David Wofsy, MD: University of California, San Francisco.

Address correspondence and reprint requests to Betty Diamond, MD, Albert Einstein College of Medicine, Department of Microbiology & Immunology and Medicine, 1300 Morris Park Avenue, Bronx, NY 10461.

Submitted for publication September 15, 2000; accepted in revised form March 27, 2001.




Figure 1. Mechanism of immune activation whereby following interaction with antigen, lymphocytes may be activated or they may be rendered inactive (“tolerant”). In the case of T cells, for example, antigen recognition occurs via the T cell receptor (TCR), which recognizes antigenic peptides (Ag) in the context of major histocompatibility complex class II (MHC II) antigens on antigen-presenting cells (APC), such as B cells or macrophages. Whether this interaction leads to T cell activation or T cell tolerance depends on other receptor–ligand pairs that provide “costimulation” to the T cell. In the presence of T cell costimulation, Ag recognition leads to T cell activation. Conversely, in the absence of T cell costimulation, Ag recognition may lead to tolerance. Many receptor–ligand pairs on the surface of T cells and APC contribute to T cell costimulation. Two particularly important costimulation pathways are shown, involving interactions between B7 molecules (on APC) and CD28 (on T cells) or between CD40 (on APC) and CD40 ligand (CD40L) (on T cells).

standing of the mechanisms involved in immune activation. As we have learned about the immune system, it has become clear that antigen alone does not activate an immune response. As Bretscher and Cohn postulated years ago (1), 2 signals are required to activate T and B lymphocytes, and this has been confirmed in recent studies (2). For activation to occur, lymphoid cells must engage antigen through an antigen receptor, either a T cell receptor (TCR) or a B cell receptor (BCR), as well as receive costimulation through other receptor–ligand pairs (3–6) (Figure 1). A major recent advance has been the identification of the critical costimulatory molecules on T and B cells and their interacting ligands on antigen-presenting cells and T cells, respectively. CD28 on T cells interacts with B7 molecules on antigen-presenting cells (3,4), while CD40 on B cells interacts with CD40 ligand on T cells (5,6). These costimulatory pairs must be engaged for cellular activation to proceed.

Activation involves both proliferation and effector function. In the case of T cells, various effector functions exist. It is well established that there are both

CD4+ helper T cells and CD8+ cytotoxic T cells (7). In addition, helper T cells may at times be classified as Th1 or Th2, depending on the panel of cytokines secreted (8,9). It is becoming increasingly evident that additional T cell subsets also exist, although their phenotypic and functional characterization is as yet incomplete. B cells are more limited in effector function, secreting antibody molecules of different isotypes.

Progress toward immune tolerance

As our knowledge of the immune system has increased, much attention has focused on the regulation of autoreactivity. It has become clear that all individuals generate autoreactive, potentially pathogenic T and B cells (10–21). Why are these cells not activated? Mechanisms exist within both primary and secondary lymphoid organs to eliminate, inactivate (anergize), or otherwise render nonpathogenic these cells. These mechanisms include deletion and anergy of autoreactive cells (14,22–27) and suppression by interacting cells or soluble factors (28–37). In the case of B cells, an additional mechanism, called receptor editing, constitutes a first defense against autoreactivity, since this mechanism provides for the generation of a new BCR to replace an autoreactive one (38,39).

Some of the mechanisms that lead to deletion and anergy are now well understood. For example, if a lymphocyte encounters antigen in the absence of a costimulatory signal, that cell will be subjected to tolerance induction, either by deletion or by induction of anergy (3–6). For autoreactive B cells developing in the bone, self tolerance may be maintained by receptor editing. Receptor editing is the process whereby an autoreactive B cell will rearrange a second light chain to generate a BCR that lacks autoreactivity (38,39). Should receptor editing not occur or fail to eliminate autoreactivity, the B cell will then be deleted or anergized (14,16,21). Autoreactive T cells similarly are deleted or anergized during thymic development (13,14). There are recent data demonstrating the existence of receptor editing for T cells also (40).

Not all autoreactive cells are tolerized as they develop in primary lymphoid organs, since not all self antigens are present in the bone marrow or the thymus. Thus, there must be mechanisms to induce tolerance of lymphocytes that encounter self antigen in the periphery. Both deletion and anergy occur in the periphery (12,16,22), but whether receptor editing occurs in the periphery remains somewhat controversial. There is in

the periphery, however, a unique mechanism of tolerance that involves the activation of regulatory cells that, through a variety of mechanisms, limit the activation of pathogenic autoreactive cells (28–37).

Despite the existence of these central and peripheral mechanisms to restrict the T and B cell repertoires and avoid autospecificity, autoreactive cells still exist in all individuals. T or B cells that elude tolerance induction may do so because of exposure to a low concentration of self antigen, too low to signal anergy or deletion, or because of a complete lack of exposure to self antigen when the antigen is sequestered away from lymphoid cells. Sometimes, the presence of autoreactive cells is masked, either because the cells have no pathogenic consequence or because there are regulatory cells that keep the autoreactive cells in check (41,42).

Immune tolerance is the normal state of an organism and is characterized by the absence of activation of pathogenic autoreactivity. As stated above, we now know that potentially pathogenic lymphocytes are generated in all individuals. These cells can be activated in an inflammatory milieu and often are activated during microbial infection due to antigenic cross-reactivity (43–45). Since activation of autoreactive cells is routine, it is evident that mechanisms are needed not only to establish tolerance, but also to restore tolerance after inflammation. Deletion of autoreactive cells is the only fail-safe mechanism of tolerance induction; however, other mechanisms can provide effective regulation under most circumstances. It is a goal of immunologists and clinicians alike to draw upon our understanding of tolerance induction of naive cells and of activated cells to devise new strategies for the treatment of autoimmune disease.

Achieving tolerance

To improve upon current immunosuppressive therapy, T and B cells must be targeted for deletion based on their antigenic specificity. Our current understanding of the ontogeny of the immune repertoire is that naive lymphoid cells encountering high concentrations of antigen in the absence of costimulation will be tolerized. It is currently thought that strong cross-linking of membrane TCR or BCR will lead to deletion, whereas less cross-linking will lead to anergy rather than deletion. This mechanism, however, does not apply to memory cells. Memory cells do not require costimulation for activation and are activated on exposure to antigen alone (46–50). Thus, soluble antigen can delete

or anergize only naive autoreactive cells. Administration of antigen, however, requires a knowledge of the antigen targeted by the pathogenic lymphocytes. The appropriate antigens for such antigen-based interventions are still unknown in the rheumatic diseases. Thus, administration of soluble antigen is a desirable strategy for tolerance induction, but the lack of identified antigens and the inability to affect memory cells limit this approach.

Just as antigen alone in the absence of a costimulatory signal can cause deletion or anergy, exposure to antigen in the context of costimulatory blockade can also induce tolerance. Animal models of SLE and RA as well as nonrheumatic autoimmune disease demonstrate that costimulatory blockade can block induction of disease (51–54). In some situations, costimulatory blockade can also abort or diminish ongoing disease. These models have generated enthusiasm for exploring the use of immune modulators that interfere with costimulatory interactions in human disease. The limitation of costimulatory blockade in lupus and RA is similar to the problem with soluble antigen as a therapeutic reagent. This approach can only tolerize naive cells. Thus, the limitations of costimulatory blockade will help teach us the extent to which disease activity relies on the continual recruitment of naive cells to an autoreactive response and the degree to which memory cells are engaged.

Some autoreactive responses are pathogenic because the cytokines that are secreted either directly mediate tissue injury or activate other cells to destroy tissue. There is substantial evidence that the autoreactive T cells in multiple sclerosis, for example, must secrete a Th1 panel of cytokines for the autoreactivity to have pathologic consequences. Autoreactive T cells of the Th2 phenotype do not cause disease (55). The effort to alter the cytokine profile of antigen-specific T cells is termed “immune deviation” and provides an approach to therapy for certain autoimmune diseases. The T cell phenotype is determined by the antigen-presenting cell and the cytokine milieu at the time that the T cell confronts antigen. Thus, strategies to present antigen in a controlled context have been proposed. This approach has, in fact, been part of the therapeutic armamentarium of the allergist for years, since desensitization involves changing the nature of T cell help such that IgG rather than IgE antibodies are produced.

Finally, autoreactive cells may be rendered non-responsive in the presence of regulatory cells. Regulatory cells that diminish the activation of autoreactive

cells clearly exist. Some time ago, these cells were termed "suppressor cells," but difficulties in their analysis led investigators to doubt their existence for a time. Recently, refinements in our characterization of T cell subsets have brought new life to this area of immunology. The exact nature of these regulatory cells remains somewhat controversial, but CD25+ cells and CD1-restricted T cells have been suggested to play a regulatory role (56,57). Transforming growth factor β appears to be a cytokine secreted by regulatory cells (58). Although studies of the activation of regulatory cells are still in their infancy, it can be anticipated that future strategies for treatment of autoimmune disease will include the selective activation of such cells.

Application to rheumatic disease

Autoimmune rheumatic diseases may reflect organ-specific autoreactivity or generalized autoreactivity. For example, RA is most commonly limited to inflammation of the joints, and myositis to muscle inflammation. SLE, in contrast, is characterized by a much broader spectrum of autoreactivity involving more autoantigens and leading to inflammatory damage in many organs. Whether different therapeutic interventions will be necessary to restore immune tolerance in organ-specific and generalized autoimmune diseases is not known. It is tempting to speculate that antigen-specific approaches may be beneficial in diseases where the target autoantigens are limited in number. In a disease like SLE, where many autoantigens are targeted by the immune system, a better approach might be a generalized dampening to thresholds for immune activation. Although this dichotomy is intellectually appealing, proof of its utility awaits successful clinical interventions in rheumatic disease that lead to disease-free periods which persist in the absence of continuous therapy.

Goals of the Immune Tolerance Network

The ITN is committed to exploring new therapeutic interventions that will lead to the cessation of unwanted, tissue-damaging immune responses. The ITN solicits and reviews proposals for clinical trials and for tolerance assays. Members of the ITN work with investigators to ensure that adequate preclinical data are available to proceed to human studies. In general, the ITN hopes to support efficacy studies, but it will fund phase I safety studies when necessary.

The ITN is also interested in learning how to identify a state of immune tolerance. To that end, it is

establishing core facilities to analyze patterns of gene expression and cellular phenotypes that characterize states of tolerance and that are altered during times of disease activity. It is hoped that these studies will provide clues to disease pathogenesis and identify surrogate markers for disease remission or flare that can be used in clinical decision-making. As yet, neither clinicians nor immunologists know the profile of the patient who has been "cured" of rheumatic disease. It is a goal of the ITN to define that profile.

Summary

The development of effective, new, biologically based therapies for RA has created real excitement and justifiable optimism in recent years among rheumatologists and among patients with rheumatic diseases. Recent advances in our understanding of the mechanisms of immune activation and immune tolerance provide further cause for optimism. Against this background, the establishment of the ITN is an important step. However, significant hurdles remain to be cleared. First, despite dramatic scientific progress, restoration of immune tolerance in the face of an established autoimmune response is still an elusive goal, even in the laboratory. Not only does the ITN face this fundamental scientific challenge, but it also faces daunting practical and political challenges. For example, can the ITN influence the research agenda of the pharmaceutical and biotechnology industries? This question and other important questions will only be answered as the ITN matures.

Autoimmune disease, although individually uncommon, affects more than 2% of Americans. The rheumatologist is especially aware of the devastating potential of autoimmune diseases. If the ITN succeeds in linking basic research into the mechanisms of autoimmunity with clinical trials of promising new therapies, it can be expected to play a critical role in advancing the practice of clinical rheumatology.

REFERENCES

1. Bretscher PA, Cohn M. Minimal model for the mechanism of antibody induction and paralysis by antigen. *Nature* 1968;166:444-8.
2. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. *Immunol Today* 1992;13:74-6.
3. Sperling AI, Bluestone JA. The complexities of T-cell co-stimulation: CD28 and beyond. *Immunol Rev* 1996;153:155-82.
4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. *Annu Rev Immunol* 1996;14:233-58.
5. Calderhead DM, Kosaka Y, Manning EM, Noelle RJ. CD40-CD154 interactions in B-cell signaling. *Curr Top Microbiol Immunol* 2000;245:73-99.

6. Vogel LA, Noelle RJ. CD40 and its crucial role as a member of the TNFR family. *Semin Immunol* 1998;10:435–42.
7. Revillard JP, Berard-Bonnefoy N. CD4, CD8, and other surface molecules regulating T-cell activation. *Immunol Ser* 1993;59:41–61.
8. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. *Annu Rev Immunol* 1997;15:297–322.
9. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 1989;7:145–73.
10. Page DM. Cutting edge: thymic selection and autoreactivity are regulated by multiple coreceptors involved in T cell activation. *J Immunol* 1999;163:3577–81.
11. Kurts C, Heath WR, Kosaka H, Miller JF, Carbone FR. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). *J Exp Med* 1998;188:415–20.
12. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, et al. Mature T lymphocyte apoptosis—immune regulation in a dynamic and unpredictable antigenic environment. *Annu Rev Immunol* 1999;17:221–53.
13. Kishimoto H, Sprent J. The thymus and central tolerance. *Clin Immunol* 2000;95:S3–7.
14. Ju ST, Matsui K, Ozdemirli M. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction. *Int Rev Immunol* 1999;18:485–513.
15. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayoub A, Malanchere E, Coutinho A, et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. *J Immunol Methods* 1998;216:117–37.
16. Pulendran B, Kannourakis G, Nouri S, Smith KG, Nossal GJ. Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. *Nature* 1995;375:331–4.
17. Gommerman JL, Carroll MC. Negative selection of B lymphocytes: a novel role for innate immunity. *Immunol Rev* 2000;173:120–30.
18. Lang J, Nemazee D. B cell clonal elimination induced by membrane-bound self-antigen may require repeated antigen encounter or cell competition. *Eur J Immunol* 2000;30:689–96.
19. Garza KM, Agersborg SS, Baker E, Tung KS. Persistence of physiological self antigen is required for the regulation of self tolerance. *J Immunol* 2000;164:3982–9.
20. Cornall RJ, Goodnow CC, Cyster JG. Regulation of B cell antigen receptor signaling by the Lyn/CD22/SHP1 pathway. *Curr Top Microbiol Immunol* 1999;244:57–68.
21. Weintraub BC, Goodnow CC. Immune responses: costimulatory receptors have their say. *Curr Biol* 1998;8:575–7.
22. Jenkins MK, Mueller D, Schwartz RH, Carding S, Bottomley K, Stadecker MJ, et al. Induction and maintenance of anergy in mature T cells. *Adv Exp Med Biol* 1991;292:167–76.
23. Salojin KV, Zhang J, Madrenas J, Delovitch TL. T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease. *Immunol Today* 1998;19:468–73.
24. Schwartz RH. T cell clonal anergy. *Curr Opin Immunol* 1998;9:351–7.
25. Powell JD, Lerner CG, Ewoldt GR, Schwartz RH. The 180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. *J Immunol* 1999;163:6331–9.
26. Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. *Cell* 1993;72:325–35.
27. Jordan MS, Riley MP, von Boehmer H, Caton AJ. Anergy and suppression regulate CD4 (+) T cell responses to a self peptide. *Eur J Immunol* 2000;30:136–44.
28. Tada Y, Ho A, Matsuyama T, Mak TW. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. *J Exp Med* 1997;185:231–8.
29. Lalani I, Bhol K, Ahmed AR. Interleukin-10: biology, role in inflammation and autoimmunity. *Ann Allergy Asthma Immunol* 1997;79:469–83.
30. Halary F, Fournie JJ, Bonneville M. Activation and control of self-reactive gammadelta T cells. *Microbes Infect* 1999;1:247–53.
31. Falcone M, Sarvetnick N. Cytokines that regulate autoimmune responses. *Curr Opin Immunol* 1999;11:670–6.
32. Gumanovskaya ML, Myers LK, Rosloniec EF, Stuart JM. Intravenous tolerization with type II collagen induces interleukin-4 and interleukin-10-producing CD4+ T cells. *Immunology* 1999;97:466–73.
33. Braun MC, Lahey E, Kelsall BL. Selective suppression of IL-12 production by chemoattractants. *J Immunol* 2000;164:3009–17.
34. Morris SC, Gause WC, Finkleman FD. IL-4 suppression of in vivo T cell activation and antibody production. *J Immunol* 2000;164:1734–40.
35. Choudhry MA, Hockberger PE, Sayeed MM. PGE2 suppresses mitogen-induced Ca2+ mobilization in T cells. *Am J Physiol* 1999;277:1741–8.
36. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. *J Immunol* 2000;164:183–90.
37. Weintraub BC, Jun JE, Bishop AC, Shokat KM, Thomas ML, Goodnow CC. Entry of B cell receptor into signaling domains is inhibited in tolerant B cells. *J Exp Med* 2000;191:1443–8.
38. Retter NW, Nemazee D. Receptor editing occurs frequently during normal B cell development. *J Exp Med* 1998;188:1231–8.
39. Chen C, Park EL, Weigert M. Editing disease-associated autoantibodies. *Immunity* 1997;6:97–105.
40. McGargill MA, Derbinski JM, Hogquist KA. Receptor editing in developing T cells. *Nat Immunol* 2000;1:336–41.
41. Malkiel S, Factor S, Diamond B. Autoimmune myocarditis does not require B cells for antigen presentation. *J Immunol* 1999;163:5265–8.
42. Bynoe MS, Spatz L, Diamond B. Characterization of anti-DNA B cells that escape negative selection. *Eur J Immunol* 1999;29:1304–13.
43. Ehrhardt RO, Ludviksson BR. When immunization leads to autoimmunity: chronic inflammation as a result of thymic and mucosal dysregulation in IL-2 knock-out mice. *Int Rev Immunol* 1999;18:591–612.
44. Hausmann S, Wucherpfennig KW. Activation of autoreactive T cells by peptides from human pathogens. *Curr Opin Immunol* 1997;9:831–8.
45. Rao VP, Kajor AE, Spindler KR, Carayanniotis G. Involvement of epitope mimicry in potentiation but not initiation of autoimmune disease. *J Immunol* 1999;162:5888–93.
46. London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. *J Immunol* 2000;164:265–72.
47. Dutton RW, Bradley LM, Swain SL. T cell memory. *Annu Rev Immunol* 1998;16:201–23.
48. Kindler V, Zubler RH. Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3. *J Immunol* 1997;159:2085–90.
49. Kuiper H, Brouwer M, de Boer M, Parren P, van Lier RA. Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation. *Eur J Immunol* 1994;24:1956–60.
50. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen: memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. *J Immunol* 1994;152:2675–85.
51. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D.

- Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. *J Immunol* 1997;159:3104–8.
52. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. *Science* 1994;265:1225–7.
 53. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat: prevention of disease by treatment with CTLA-4-Ig. *J Clin Invest* 1995;96:987–93.
 54. Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. *Eur J Immunol* 1996;26:2320–8.
 55. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Bergh F, Dose T, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. *Proc Natl Acad Sci U S A* 2000;97:7452–7.
 56. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. *Immunity* 2000;12:431–40.
 57. Mieza MA, Itoh T, Cui JQ, Makino Y, Kawano T, Tsuchida K, et al. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. *J Immunol* 1996;156:4035–40.
 58. Ludviksson BR, Seegers D, Resnick AS, Strober W. The effect of TGF-beta1 on immune responses of naive versus memory CD4+ Th1/Th2 T cells. *Eur J Immunol* 2000;30:2101–11.